Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register
暂无分享,去创建一个
[1] A. Kiadaliri,et al. Brief Report: Rheumatoid Arthritis as the Underlying Cause of Death in Thirty‐One Countries, 1987–2011: Trend Analysis of World Health Organization Mortality Database , 2017, Arthritis & rheumatology.
[2] M. Lunt,et al. Twenty‐Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register , 2017, Arthritis & rheumatology.
[3] T. Therneau,et al. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? , 2017, The Journal of Rheumatology.
[4] S. Norton,et al. Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States , 2017, Arthritis care & research.
[5] C. Bombardier,et al. Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada , 2015, Arthritis care & research.
[6] M. Lunt,et al. Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register , 2014, Arthritis care & research.
[7] M. Lunt,et al. Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time? , 2014, The Journal of Rheumatology.
[8] M. P. Lozano,et al. FRI0296 Is There A Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab in Patients with Rheumatoid Factor Positive and Negative? A Systematic Review , 2014 .
[9] Désirée van der Heijde,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.
[10] P. Emery,et al. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis , 2013, Annals of the rheumatic diseases.
[11] D. M. van der Heijde,et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). , 2011, Arthritis and rheumatism.
[12] John Wong,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.
[13] A. Davis,et al. Patient Satisfaction after Total Knee Arthroplasty: Who is Satisfied and Who is Not? , 2010, Clinical orthopaedics and related research.
[14] D. Symmons,et al. Mortality in established rheumatoid arthritis. , 2007, Best practice & research. Clinical rheumatology.
[15] M. Liang,et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.
[16] P. V. van Riel,et al. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. , 2005, Arthritis and rheumatism.
[17] Andrea Messori,et al. New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .
[18] L. Kay,et al. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. , 2004, Rheumatology.
[19] N. Olsen,et al. New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.
[20] T. Pincus,et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.
[21] J. Arokoski,et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality , 2003, Annals of the rheumatic diseases.
[22] E. Cook,et al. The importance of patient expectations in predicting functional outcomes after total joint arthroplasty. , 2002, The Journal of rheumatology.
[23] James M Robins,et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.
[24] Alison J. Carr,et al. An Ethical Dilemma Medical Errors and Medical Culture an Error of Omission Education and Debate , 2022 .
[25] A. Silman,et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. , 2001, Arthritis and rheumatism.
[26] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[27] A. Silman,et al. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.
[28] J. Kirwan,et al. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. , 1986, British journal of rheumatology.
[29] Laure Gossec,et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. , 2013, Joint, bone, spine : revue du rhumatisme.
[30] Mark Lunt,et al. Early treatment with , and time receiving , fi rst disease-modifying antirheumatic drug predicts long-term function in patients with infl ammatory polyarthritis , 2010 .
[31] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[32] A. Silman,et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.
[33] O Wiegman,et al. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. , 1999, Patient Education and Counseling.